Pharma & Biotech — 2026年11月1日 月次レポート
Pharma & Biotechのニュース＆アップデート — すべての記述に一次ソースのリンク付き。
重要な発見
エグゼクティブサマリー（5件）
- •October 2026 delivered the mRNA cancer vaccine's Phase 3 confirmation and a wave of record-value China licensing deals, but ended with the US Treasury proposing COINS Act investment restrictions on Chinese biotech — marking the month where the China-sourced pipeline model began its structural transition from open partnership to licensed-only access.
- •The UK's regulatory modernisation agenda — AI Commission endorsement, MHRA AI Airlock Phase 3, and the 2030 Strategy — created the world's most advanced AI medicines regulatory framework in a single month, establishing a first-mover advantage that the EU is now under industry pressure to match.
- •J&J and Merck dominated competitive execution: J&J through financial outperformance, multiple myeloma regulatory advance, and a novel prostate cancer platform; Merck through the mRNA vaccine Phase 3 win and a new European bladder cancer approval, despite the subcutaneous Keytruda court setback in Europe.
- •The GLP-1 platform's expansion into oral formulations, addiction indications, and direct-to-consumer channels — combined with counterfeit seizures and off-label telehealth prescribing — signals the class is transitioning from a pharmaceutical product to a consumer health and behavioural health platform faster than regulatory frameworks can accommodate.
- •The pharmaceutical tariff regime and COINS Act proposal together are restructuring the industry's competitive economics: large incumbents gain tariff shelter via MFN agreements while smaller biotechs bear immediate costs, and the COINS carve-out preserving drug rights licensing while prohibiting equity investment will accelerate a shift from partnership to pure licensing in US-China biotech relationships.
今回の要点（8件）
- 1.The Merck-Moderna mRNA cancer vaccine program completed its journey from Phase 3 planning (reported in Week 3) to confirmed Phase 3 success at the ESMO 2026 Presidential Symposium (Week 4), with detailed INTerpath-001 data confirming the vaccine met key endpoints in melanoma [8]. This converts the July–August 2026 co-primary endpoint announcement into a fully validated clinical milestone and opens the question of how broadly the platform can be applied across solid tumor indications.
- 2.China-sourced licensing dominated October deal flow — Novo Nordisk paid $300M upfront for Hengrui's oral GLP-1/GIP agonist, Novartis paid $575M upfront for Abogen's mRNA T cell engager, Merck licensed a KRAS G12D inhibitor from SciBrunch for $400M upfront, Roche struck its fourth China deal since August with Defand Therapeutics, and then closed a $15B deal with Hansoh for ADCs, while Gilead paid $1.3B upfront for an oral IL-23 drug [16] — yet by month-end the US Treasury proposed COINS Act restr…
- 3.The UK established itself as the world's most advanced regulatory jurisdiction for AI-enabled medicines across the month: the government backed the NHS AI Commission recommendations in full (Week 2), the MHRA AI Airlock opened Phase 3 applications, and the MHRA published its 2030 Strategy formalising a multi-year AI and personalised medicine regulatory roadmap (Week 3) [11] — prompting EFPIA to call for a single EU regulatory pathway for AI-enabled medical technologies the following day.
- 4.The US pharmaceutical tariff regime created asymmetric competitive pressure throughout the month: a 100% section 232 tariff on imported pharmaceuticals took effect at end of September, with large MFN-agreement holders exempt until 2029 but smaller biotechs facing immediate costs [14]. GSK's simultaneous announcement of 1,217 Belgium job cuts and an $800M US manufacturing investment illustrated the geographic rebalancing incentive the tariff regime is creating across the sector.
- 5.J&J was the month's strongest financial and pipeline performer: Q3 2026 sales of $25.4 billion with 5.9% reported growth and raised 2026 guidance to $101.2 billion at the midpoint [10], combined with CHMP recommendation for TALVEY plus daratumumab in multiple myeloma, ESMO data for the novel RIPTAC platform showing 75% tumor response in prostate cancer, and ERLEADA reducing recurrence risk by 62% in high-risk prostate cancer.
- 6.The GLP-1 platform continued its commercial and clinical expansion: the EMA's CHMP recommended a once-daily oral GLP-1 tablet (Week 3), Eli Lilly's Zepbound combined with an amylin drug posted best-ever weight loss data, telehealth companies began marketing off-label GLP-1 prescriptions for addiction ahead of FDA approval (Week 4), and the MHRA seized £2 million in counterfeit weight loss pens — collectively signalling the class is transitioning from injectable obesity treatment to a broad oral …
- 7.A patient death in a Bristol Myers Squibb autoimmune CAR-T trial (Week 4) introduced a safety overhang for the autoimmune CAR-T field [8], arriving at the same time that Caribou Biosciences shut down after failing to fund a CAR-T lymphoma trial despite FDA-aligned Phase 3 design — together illustrating that the cell therapy field faces both capital concentration risk and safety scrutiny simultaneously.
- 8.Merck faced a material European setback when a Dutch court ordered it to stop manufacturing and selling its subcutaneous Keytruda formulation in eight European countries (Week 2) [7], constraining the patient convenience differentiator of its flagship oncology product in a major market even as the company advanced its pipeline at ESMO and secured a new European Commission approval for KEYTRUDA plus Padcev in bladder cancer.
市場動向
mRNA Cancer Vaccine Platform Transitions From Proof-of-Concept to Validated Oncology Franchise
The Merck-Moderna mRNA cancer vaccine program progressed across all four weeks of October: from active planning discussions (Week 3, STAT News reporting the partners 'have a lot of exploring to do') to full Phase 3 confirmation at the ESMO Presidential Symposium (Week 4), where INTerpath-001 data confirmed the vaccine met key endpoints in melanoma [8]. This builds directly on the July–August 2026 co-primary endpoint announcement and converts it into a validated clinical milestone. The competitiv…
China Biotech Sourcing Peaks Then Faces Structural Constraint
October saw the highest concentration of China-sourced licensing deals on record — Novo/Hengrui ($300M upfront), Novartis/Abogen ($575M upfront), Merck/SciBrunch ($400M upfront), Roche/Defand (up to ~$1B), Roche/Hansoh ($400M upfront, up to $15B), and Gilead's $1.3B upfront oral IL-23 deal [16] — reflecting the continuation of the trend identified in July–August 2026. However, by Week 4 the US Treasury proposed COINS Act restrictions prohibiting equity investment in Chinese biotech [15] and Chin…
GLP-1 Platform Expands Across Oral Formulations, Behavioural Health, and Consumer Channels
The GLP-1 market's commercial repositioning — identified in Week 1 as a shift from disease treatment to consumer lifestyle product — accelerated across the month. The EMA's CHMP recommended a once-daily oral GLP-1 tablet in Week 3 [3], marking a formulation inflection point for the class. By Week 4, telehealth companies were already marketing off-label GLP-1 prescriptions for addiction ahead of FDA approval [8a], and the MHRA seized £2 million in counterfeit weight loss pens. Lilly's direct-to-c…
Molecular Glue Platform Achieves Clinical and Regulatory Validation
Molecular glues transitioned from a niche chemistry concept to a mainstream platform across October. Revolution Medicines' Rasonque — described by Nature Biotechnology as the first molecular glue treatment to demonstrate clinical validation in pancreatic cancer [9] — received EMA CHMP recommendation via phased review in Week 3. Roche struck a co-discovery deal with Defand Therapeutics for molecular glue medicines in Week 2, and Nature Biotechnology published a scalable platform for discovering m…
AI Drug Discovery Investment Enters Validation Phase Under Growing Scrutiny
AI drug discovery funding remained active throughout October — Pathos raised $237M at a $3B valuation (Week 4) [8], City Therapeutics landed a $200M IPO, and Iambic raised $150M for an AI-driven cancer pipeline (Week 3). However, STAT News reported growing scrutiny of whether Isomorphic Labs has what it takes to revolutionise drugmaking, and Nature Biotechnology highlighted Bioptimus's multimodal AI pathology models as an editor's pick. The sector is entering a validation phase where capital dep…
競合動向
J&J Sustains Multi-Front Dominance Across Financial Performance, Oncology, and Immunology
J&J was the month's most consistent performer across all four weeks. It extended two-year ICOTYDE durability data in psoriasis (Weeks 1–2), reported Q3 2026 sales of $25.4 billion with raised 2026 guidance to $101.2 billion at the midpoint (Week 3) [10], received CHMP recommendation for TALVEY plus daratumumab in earlier-line multiple myeloma with up to 81% progression-free survival at 24 months, and at ESMO presented the first RIPTAC platform readout showing 75% tumor response in prostate cance…
Merck Advances Pipeline While Managing European Keytruda Setback
Merck's October trajectory combined significant wins with a material setback. A Dutch court blocked its subcutaneous Keytruda formulation in eight European countries (Week 2) [7], constraining its flagship product's next-generation formulation in a major market. Against this, Merck licensed the KRAS G12D inhibitor SPR2015 for $400M upfront (Week 1), showcased pivotal Phase 3 oncology data at ESMO (Week 3), received European Commission approval for KEYTRUDA plus Padcev in bladder cancer (Week 4),…
Roche Pursues Aggressive China-Sourced Pipeline Rebuilding While Rationalising Internally
Roche executed the most aggressive China deal-making of any Western company in October: a co-discovery deal with Defand Therapeutics for molecular glues (Week 2, its fourth China deal since August), and a $15B deal with Hansoh for ADCs with $400M upfront (Week 4) [16], plus a $813M deal with Zymeworks for a preclinical T cell engager. Simultaneously, Roche unveiled pipeline cuts (Week 4) [7]. This pattern — replacing internal pipeline attrition with externally sourced Chinese assets — is now dir…
Bristol Myers Squibb Faces Autoimmune CAR-T Safety Overhang
A patient death in BMS's autoimmune CAR-T MS trial (Week 4) [8] introduced a significant safety overhang for the company's cell therapy program at a moment when autoimmune CAR-T was being positioned as a potential cure for lupus and MS. BMS also addressed a safety signal in a lupus trial in the same week. This safety development, combined with Caribou Biosciences' shutdown (Week 2) due to funding failure despite FDA-aligned Phase 3 design, illustrates the dual pressures — safety scrutiny and cap…
GSK and Pfizer Execute Selective Advances Amid Structural Repositioning
GSK announced 1,217 Belgium job cuts while simultaneously committing $800M to a new US R&D and manufacturing hub (Week 3) [7] — a geographic rebalancing driven by US tariff incentives — and received FDA approval for a hepatitis B functional cure drug (Week 4). Pfizer secured FDA approval for TUKYSA as front-line HER2+ metastatic breast cancer maintenance (Week 2) [6] and reported positive Phase 2 data for tilrekimig in atopic dermatitis and LITFULO in vitiligo (Week 1), building an immunodermato…
制度・規制動向
UK Builds World's Most Advanced AI Medicines Regulatory Framework in a Single Month
The UK's regulatory modernisation accelerated through three sequential milestones: the government backed the NHS AI Commission recommendations in full and the MHRA AI Airlock opened Phase 3 applications (Week 2) [11], followed by the MHRA's 2030 Strategy publication formalising a multi-year AI and personalised medicine regulatory roadmap (Week 3). The MHRA also expanded its 14-day Phase 1 assessment programme to non-oncology patient studies, bioequivalence, DDI, and QT studies targeting first wa…
US-China Biotech Regulatory Confrontation Escalates From Tariffs to Investment Restrictions
The US regulatory posture toward China-sourced biotech hardened progressively across October. A 100% section 232 tariff on imported pharmaceuticals took effect at end of September, with asymmetric impact on smaller biotechs lacking MFN agreements [14]. PhRMA filed suit against the Trump administration's GLOBE Medicare MFN pilot (Week 2). By Week 4, the Treasury proposed COINS Act rules adding biotech to national security outbound investment restrictions [15], while China simultaneously moved to …
EMA Maintains High Approval Throughput and Institutionalises Pre-Submission Support
The EMA's CHMP October meeting recommended six new medicines including an oral GLP-1 tablet and J&J's TALVEY combination for multiple myeloma, and authorised Rasonque for pancreatic cancer via phased review [3]. The EMA also made its clinical trial application advice pilot permanent from January 2027, providing sponsors a concrete planning horizon for pre-submission support across the EU. The EMA and AMA issued joint Ebola vaccine development guidance in Week 4, operationalising the pandemic pre…
Global Regulators Converge on Animal Testing Alternatives and AI Device Standards
MHRA and EMA jointly called for advancing alternatives to animal testing across the medicine lifecycle in Week 1, with international harmonisation as a key pillar [3]. Japan's PMDA published English translations of its AI-enabled medical device review criteria and draft AI device review points across Weeks 3–4 [4], signalling deliberate internationalisation of its AI regulatory framework. The FDA published guidance on drug-related software and clinical trial data submission for driving studies (…
ソース活動
先月からの変化
Merck Licenses KRAS G12D Inhibitor SPR2015 for $400M Upfront
Merck entered an exclusive global license with SciBrunch Therapeutics for SPR2015, an oral KRAS G12D (ON) inhibitor, paying $400M upfront in a deal valued at $2.13 billion [2]. Extends Merck's oncology pipeline into the KRAS mutation space following Revolution Medicines' first approved KRAS inhibitor in July–August 2026.
HHS Launches SURPASS AI Clinical Trial Modernization Program Through ARPA-H
HHS announced the five-year SURPASS program through ARPA-H on 2026-09-30, incorporating AI and computational models into clinical trial design and explicitly framed as a competitive response to China's faster trial environment [8b]. The FDA simultaneously launched a new clinical trial modernization office within CDER.
MHRA Expands 14-Day Phase 1 Trial Assessment Programme Eligibility
The MHRA expanded its 14-day assessment programme on 2026-09-30 to include non-oncology patient Phase 1 studies, bioequivalence, DDI, mass balance, and QT studies, targeting first wave 1 delivery in 14 calendar days by end of December 2026 [12].
Beam Therapeutics Sues YolTech and Serapha Bio for Gene-Editing IP Theft
Beam Therapeutics filed suit alleging a former scientist used stolen electronic laboratory notebook data to co-found YolTech Therapeutics in Shanghai, which then partnered with RA Capital and RTW to form Serapha Bio [8c]. The most prominent IP theft allegation in US-China biotech this year.
UniQure Huntington's Gene Therapy Shows Waning Benefit at Four Years
UniQure's AMT-130 slowed Huntington's disease progression by 44% at four years versus an external control, down from 75% at three years, with the difference not statistically significant [8d]. Raises durability questions as the FDA reviews the marketing application.
Dutch Court Blocks Merck's Subcutaneous Keytruda in Eight European Countries
A Dutch court ordered Merck to stop manufacturing and selling its subcutaneous Keytruda formulation in eight European countries [7]. Material commercial setback for Merck's flagship oncology franchise, constraining the patient convenience differentiator of its most important product in a major market.
UK Government Backs AI Commission Recommendations; MHRA AI Airlock Phase 3 Opens
On 2026-10-06, the UK government backed in full the NHS doctors-led National Commission's AI healthcare regulatory recommendations, and the MHRA AI Airlock opened Phase 3 applications [11]. Makes the UK the first major jurisdiction with a comprehensive government-endorsed AI healthcare regulatory framework.
EMA Clinical Trial Application Advice Pilot Made Permanent From January 2027
The EMA announced on 2026-10-08 that its clinical trial applications advice pilot will become a permanent service from January 2027 [3], providing ongoing pre-submission support for sponsors and reducing uncertainty for EU clinical trial applications.
Pfizer's TUKYSA Receives FDA Approval as Front-Line HER2+ Metastatic Breast Cancer Maintenance
Pfizer's TUKYSA regimen received FDA approval as front-line maintenance treatment for HER2-positive metastatic breast cancer on 2026-10-07 [6], extending the label into an earlier treatment setting and expanding the addressable patient population.
Caribou Biosciences Shuts Down; CAR-T Funding Gap Illustrated
Caribou Biosciences, co-founded by CRISPR Nobel laureate Jennifer Doudna, shut down after failing to raise funding for a late-stage CAR-T lymphoma trial despite having finalized Phase 3 design with the FDA [8e]. Illustrates that scientific credibility and regulatory alignment are insufficient without investor capital.
100% Section 232 Pharmaceutical Import Tariff Takes Effect; Asymmetric Burden on Smaller Biotechs
A 100% section 232 tariff on imported pharmaceuticals and active ingredients took effect at end of September 2026, with large MFN-agreement holders exempt until 2029 but smaller biotechs facing immediate costs and limited guidance on exemptions [14].
PhRMA Sues Trump Administration Over GLOBE Medicare MFN Pilot
PhRMA filed a lawsuit asserting the GLOBE most-favored nation pilot in Medicare Part B exceeds Medicare's statutory authority [8f], escalating the legal confrontation over drug pricing policy alongside the pharmaceutical tariff regime.
MHRA Publishes 2030 Strategy for AI and Personalised Medicine Regulation
The MHRA published its 2030 Strategy on 2026-10-14, formalising a multi-year roadmap for AI and personalised medicine regulation across all four UK nations [11]. Builds on the prior week's AI Commission endorsement and AI Airlock Phase 3 opening, providing a concrete planning horizon for AI-enabled product development in the UK.
EMA Recommends Oral GLP-1 Tablet and Rasonque for Pancreatic Cancer
The EMA's CHMP October 2026 meeting recommended authorisation of a once-daily oral GLP-1 medicine for weight management and type 2 diabetes, and separately recommended Rasonque (Revolution Medicines) for metastatic pancreatic cancer via phased review on 2026-10-15 [3]. The oral GLP-1 marks a formulation inflection point; Rasonque validates the molecular glue platform at the regulatory level.
J&J Reports Q3 2026 Results With Raised Guidance; CHMP Recommends TALVEY Combination
J&J reported Q3 2026 sales of $25.4 billion (5.9% reported growth) and raised 2026 guidance to $101.2 billion at the midpoint on 2026-10-13 [10]. The CHMP recommended TALVEY plus daratumumab for earlier-line relapsed/refractory multiple myeloma with Phase 3 data showing progression-free survival of up to 81% at 24 months.
Chinese Government Pursues Export Ban on Select Biopharma Technology
Endpoints News reported on 2026-10-16 that the Chinese government is pursuing an export ban on select biopharma technology [7], introducing a new adversarial dimension to the US-China biotech relationship that could disrupt co-discovery partnerships Western pharma has been building.
GSK Announces Belgium Job Cuts and $800M US Manufacturing Investment
GSK announced plans to make up to 1,217 workers redundant in Belgium while simultaneously investing $800 million in a new US R&D and manufacturing hub in Pennsylvania [7], reflecting geographic rebalancing driven by US pharmaceutical tariff incentives.
US Treasury Proposes COINS Act Biotech Investment Restrictions on China
The Trump administration proposed on 2026-10-23 a rule under the COINS Act adding biotechnology to national security outbound investment restrictions, prohibiting US companies from entering financial transactions with Chinese biotech companies while still allowing drug rights purchases [15]. The most consequential US regulatory action affecting pharma-China relationships this period.
Merck-Moderna mRNA Cancer Vaccine Phase 3 Data Confirmed at ESMO
Merck and Moderna presented Phase 3 INTerpath-001 results at the ESMO 2026 Presidential Symposium, with STAT News confirming on 2026-10-23 that detailed data confirmed the cancer vaccine met key endpoints in melanoma [8]. Updates the July–August 2026 co-primary endpoint announcement (ic-w16) — the program has now achieved full Phase 3 confirmation.
Bristol Myers Squibb Patient Death in Autoimmune CAR-T Trial
A patient died in a Bristol Myers Squibb autoimmune CAR-T MS trial, reported by STAT News on 2026-10-23 [8]. BMS also addressed a safety signal in a lupus trial. Introduces a significant safety overhang for BMS's autoimmune CAR-T program and the broader field.
China Biotech Decoupling Intensifies: Bidirectional Restrictions Confirmed
China moved to restrict foreign biotech acquisitions (STAT News, 2026-10-19) [8g] while the US Treasury proposed COINS restrictions on outbound biotech investment (2026-10-23) [15]. Despite this, Roche and Gilead completed major China licensing deals, illustrating the tension between geopolitical restrictions and commercial drug sourcing imperatives. Updates ic-oct-16.
Roche Strikes $15B Hansoh ADC Deal and Gilead Pays $1.3B Upfront for Oral IL-23
Roche struck a deal with Hansoh Pharmaceutical Group worth up to $15 billion with $400 million upfront for a portfolio of antibody-drug conjugates [16], and Gilead struck a $1.3 billion upfront China deal for an oral IL-23 drug [7]. Both deals were completed in the same week the COINS Act proposal was announced.
J&J RIPTAC Platform Shows 75% Tumor Response in Prostate Cancer Phase 1
J&J reported on 2026-10-25 that its first-in-class RIPTAC molecule JNJ-6143 achieved a 75% tumor response rate in advanced prostate cancer in Phase 1, with 77% of patients achieving a confirmed PSA reduction of at least 50% [10]. First clinical validation of the RIPTAC targeted dual-protein lock platform.
GSK Receives FDA Approval for Hepatitis B Functional Cure Drug
GSK received FDA approval for a hepatitis B drug offering a functional cure, reported by Endpoints News on 2026-10-21 [7]. Represents a significant competitive advance in infectious disease, positioning GSK ahead of competitors still in development for this long-sought goal.
MHRA Delivers Multiple New Drug Approvals and Confirms Indefinite CE Mark Recognition
The MHRA authorised plozasiran (Redemplo) for familial chylomicronaemia syndrome, approved a new oral plaque psoriasis treatment and deuruxolitinib (Leqselvi) for alopecia areata, and confirmed indefinite recognition of CE marked medical devices on 2026-10-21 [11]. Removes a major post-Brexit uncertainty for medical device manufacturers.
示唆・見るべき論点（8件）
- 1.The COINS Act proposal's structural carve-out — prohibiting equity investment in Chinese biotech while preserving drug rights licensing [15] — will accelerate a shift from co-discovery and equity partnership models (exemplified by Roche/Defand) to pure licensing arrangements. Companies currently in co-discovery structures with Chinese partners should audit whether those arrangements involve financial transactions that would be prohibited under the proposed rule and begin restructuring toward lic…
- 2.The Merck-Moderna Phase 3 confirmation at ESMO [8] transforms the competitive calculus for personalised oncology: every major oncology company must now assess whether to develop its own mRNA neoantigen vaccine program or risk ceding the adjuvant melanoma market — and potentially other solid tumor indications — to the Merck-Moderna partnership. The BioNTech-Genentech Phase 2 termination in July–August 2026 established that neoantigen selection algorithms are the critical differentiator; companies…
- 3.The UK's regulatory trifecta — AI Commission endorsement, MHRA AI Airlock Phase 3, and the 2030 Strategy [11] — creates a first-mover regulatory advantage for AI-enabled medicines that the EU has not yet matched. Companies developing AI-enabled diagnostics, drug discovery tools, or personalised medicines should treat the UK as the primary regulatory entry market for AI-enabled products in 2027, as the combination of the AI Airlock sandbox and the 2030 Strategy provides regulatory predictability …
- 4.The pharmaceutical tariff's asymmetric structure — exempting large MFN-agreement holders until 2029 while exposing smaller biotechs to immediate costs [14] — combined with the COINS Act proposal is likely to accelerate M&A consolidation: smaller companies with imported API dependencies or Chinese co-discovery partnerships face compounding cost and compliance pressures that larger acquirers' MFN agreements and legal resources can absorb. Biotech companies in this position should model acquisition…
- 5.The BMS autoimmune CAR-T patient death [8] and Caribou's shutdown despite FDA-aligned Phase 3 design [8e] together signal that the autoimmune and off-the-shelf CAR-T fields face a dual credibility problem entering November: safety scrutiny from regulators and capital concentration from investors. Companies with autoimmune CAR-T programs should proactively engage regulators on safety monitoring protocols and prioritise demonstrating cost-of-goods advantages over autologous approaches in investor …
- 6.The GLP-1 platform's expansion into off-label addiction prescribing via telehealth [8a], combined with the MHRA's £2 million counterfeit seizure and the EMA's oral GLP-1 recommendation, signals that the class is outpacing its regulatory governance simultaneously in three dimensions: indication expansion, formulation evolution, and illicit market growth. Companies with GLP-1 programs in addiction indications should accelerate regulatory submissions to establish approved labelling before the off-l…
- 7.The EMA's permanent clinical trial application advice service from January 2027 [3], combined with the MHRA's 14-day Phase 1 assessment expansion and the FDA's SURPASS program, means all three major regulatory jurisdictions are now actively competing for clinical trial sponsors through pre-submission support and accelerated timelines. Companies planning Phase 1 or early-phase studies in 2027 should conduct a comparative regulatory pathway analysis across the UK, EU, and US before committing to a…
- 8.J&J's first RIPTAC platform readout showing 75% tumor response in prostate cancer [10] represents the first clinical validation of a targeted dual-protein lock mechanism distinct from existing small molecule approaches. If confirmed in larger trials, this could establish a new class of targeted protein degraders with implications beyond prostate cancer — and positions J&J to own a novel modality in solid tumors at a time when its bispecific antibody combinations are already setting efficacy benc…
信頼度サマリー
今週引用したソース 16 件あなたが選んだ 15 件の監視URLから検出（1つのURLから複数記事が出ることがあります）。
各ソースは信頼度レベルに応じて重み付けされています。単独ソースの主張は AI 合成時に未検証としてフラグ付けされます。
参照ソース一覧
IFPMA statements across WHO forums on pandemic preparedness, AI in public health, and global health architecture reform; Director General expert insight on pharmaceutical innovation as strategic national asset.
Merck press releases covering KRAS G12D licensing deal with SciBrunch, tulisokibart Phase 2b data, ESMO oncology data presentations, KEYTRUDA European Commission approval for bladder cancer, and mRNA cancer vaccine ESMO announcement.
EMA news covering CHMP October meeting recommendations including oral GLP-1 tablet and Rasonque for pancreatic cancer, permanent clinical trial application advice pilot, joint Ebola vaccine guidance, and MHRA-EMA joint call on animal testing alternatives.
PMDA publications including GMP/GCTP annual report, AI-enabled medical device review criteria English translation, biosimilar standards updates, 20th Japanese Pharmacopoeia revision policy, and companion diagnostic guidance.
EFPIA joint statement calling for single regulatory pathway for AI-enabled medical technologies across Europe; continued advocacy on Urban Wastewater Treatment Directive pause.
Pfizer press releases covering TUKYSA FDA approval as front-line HER2+ metastatic breast cancer maintenance, tilrekimig Phase 2 atopic dermatitis data, and LITFULO vitiligo data.
Endpoints News reporting on Dutch court Keytruda ruling, Caribou Biosciences shutdown, BioNTech manufacturing site closures, GSK Belgium job cuts and US investment, Roche pipeline cuts and China deals, BMS CAR-T patient death, Gilead China IL-23 deal, and GSK hepatitis B approval.
STAT News reporting on China biotech ascendancy, Beam Therapeutics IP lawsuit, SURPASS program, UniQure Huntington's data, Caribou shutdown, pharmaceutical tariffs, COINS Act proposal, Roche Hansoh deal, BMS CAR-T death, mRNA cancer vaccine ESMO confirmation, and GLP-1 addiction off-label prescribing.
Nature Biotechnology research on molecular glue degrader substrate discovery platform, AI-guided mRNA vaccine optimization, and Rasonque as first molecular glue clinical validation in pancreatic cancer.
J&J press releases covering Q3 2026 financial results, TALVEY plus daratumumab CHMP recommendation, RIPTAC platform Phase 1 prostate cancer data, ERLEADA perioperative data, and ICOTYDE psoriasis durability data.
MHRA regulatory actions including 2030 Strategy publication, AI Airlock Phase 3 opening, antidepressant safety information update, counterfeit weight loss pen seizure, once-weekly insulin Onswik authorisation, multiple new drug approvals, and indefinite CE mark recognition confirmation.
MHRA 14-day Phase 1 assessment stepwise implementation programme update expanding eligibility to non-oncology patient studies, bioequivalence, DDI, mass balance, and QT studies.
FDA drug news covering biosimilar development Q&A guidance updates, postapproval manufacturing change guidance, study data technical conformance guide update, and new guidance on clinical trial data submission and drug-related software.
STAT News reporting on 100% section 232 pharmaceutical import tariff impact on smaller biotech companies and asymmetric burden relative to large MFN-agreement holders.
STAT News reporting on US Treasury COINS Act proposal adding biotechnology to national security outbound investment restrictions while preserving drug rights licensing from China.
STAT News reporting on Roche's $15 billion deal with Hansoh Pharmaceutical Group for a portfolio of antibody-drug conjugates with $400 million upfront.
Pharma & Biotechを毎週、自動で監視
このレポートは一次ソースのみから生成されています。テーマとソースを選べば、引用付きレポートが毎週届きます。7日間無料トライアル・$33/月から。
無料トライアルを始める